FDA more receptive to Correvio's second Brinavess NDA

25 July 2019

Almost two years after the US Food and Drug Administration (FDA) snubbed Correvio Pharma Corp’s (Nasdaq: CORP) filing for Brinavess (vernakalant hydrochloride, IV), the agency has accepted the New Drug Application (NDA).

The FDA cited insufficient data in refusing to accept the initial submission in August 2017, but has not demanded any additional studies be done on Brinavess (vernakalant hydrochloride, IV), the treatment for atrial fibrillation (AF) which has already been approved for marketing in Europe, Canada and several other countries worldwide.

In its acceptance letter, the FDA stated that it is currently planning to hold an advisory committee meeting to discuss the resubmitted NDA to market the antiarrhythmic drug for the rapid conversion of recent onset AF to sinus rhythm in adult patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK